PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantationPhilippe Armand, Alex F. Herrera, Yi‐Bin Chen et al.|Blood|2019Cited by 187
A phase 2 study of Rituximab‐Bendamustine and Rituximab‐Cytarabine for transplant‐eligible patients with mantle cell lymphomaPhilippe Armand, Eric D. Jacobsen, Robert Redd et al.|British Journal of Haematology|2016Cited by 68
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantationMatthew J. Frigault, Robin Joyce, Parastoo B. Dahi et al.|Blood Advances|2020Cited by 65
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphomaReid W. Merryman, Eric D. Jacobsen, Natasha Edwin et al.|Blood Advances|2020Cited by 58
Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemiaBenjamin L. Lampson, Jennifer R. Brown, Matthew S. Davids et al.|Blood Advances|2019Cited by 29